Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Biohaven Completes Randomization in Phase 2/3 Trial in Spinocerebellar Ataxia

americanpharmaceuticalreviewAugust 08, 2017

Tag: Biohaven , Spinocerebellar Ataxia

PharmaSources Customer Service